Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

February 19, 2019

Annual volume, revenue exceed increased guidance for full-year 2018
Guided to more than 500,000 test samples, $220 million in revenue expected in 2019
Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018.

“In just five years, we have provided more than half a million people with high quality, comprehensive ...

Read more


Invitae to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Invitae to Present at the 8th Annual SVB Leerink Global Healthcare Conference

February 13, 2019

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 a.m. Eastern / 8:30 a.m. Pacific in New York City.

A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be ...

Read more


Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy

Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy

February 12, 2019

In Combination with Carrier Screening, NIPS Provides Affordable, Streamlined Access to Genetic Testing for Parents-to-Be

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced the addition of non-invasive prenatal screening (NIPS) to the company’s comprehensive women’s health genetic testing services, providing patients with easier access to affordable genetic testing in early pregnancy. In combination with the expanded carrier screening (ECS), Invitae now offers integrated testing using the two most common prenatal genetic tests, with in-depth follow-up testing available for ...

Read more


New Study Finds Disease-Causing Variants More Common in Men with Prostate Cancer Than Previously Thought

New Study Finds Disease-Causing Variants More Common in Men with Prostate Cancer Than Previously Thought

February 07, 2019

Largest Dataset of Prostate Cancer Patients Shows 17% Have Increased Risk Based on Genetic Analysis

Testing Guidelines Still Exclude At-Risk Patients

The largest study to date on the genetics of prostate cancer has found that 17 percent of prostate cancer patients are born with genetic variants that can be associated with higher risk of various cancers. The study was published today in JAMA Oncology by researchers from Tulane Cancer Center and Invitae (NYSE: NVTA), a leading genetics company. In addition ...

Read more


Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond

Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyond

January 07, 2019

Delivered more than 302,000 samples, generating revenue of more than $144 million in 2018

Provides 2019 guidance of more than 500,000 sample test volume and more than $220 million in 2019 revenue

Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, announced preliminary unaudited full-year 2018 results showing triple-digit growth driven by strong commercial execution, test menu expansion and the accelerating use of genetics in healthcare.

“We envisioned a world in which genetic information can inform healthcare ...

Read more


New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients

New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients

December 10, 2018

Data shows current guidelines exclude many patients with medically relevant genetic changes

Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians and Invitae (NYSE: NVTA), one of the fastest growing genetics companies. The findings support broadening and ...

Read more


Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference

Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference

November 14, 2018

Research highlights frequency of medically actionable variants among secondary findings

Code Talker Award honors excellence in genetic counseling

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, are presenting research at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that further underscores the frequency of medically actionable genetic variants and their utility in clinical care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence ...

Read more


Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018

Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018

November 07, 2018

Raising annual volume and revenue guidance amid strong performance
Q3 2018 gross profit of $16.9M up from nearly $5.0M in Q3 2017
Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the third quarter ended September 30, 2018. Based on progress in the quarter, Invitae is raising its volume guidance from more than 275,000 ...

Read more


Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria

Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria

October 29, 2018

Part of Invitae’s network of partnerships, program supports early diagnosis to help patients and their clinicians make more informed decisions about their health

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing at no cost to patients through the Alnylam Act® program for individuals who may carry gene mutations associated with primary hyperoxaluria, an ultra-rare genetic disorder affecting ...

Read more


Invitae to announce third quarter 2018 financial results on November 7, 2018

Invitae to announce third quarter 2018 financial results on November 7, 2018

October 24, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number ...

Read more